Comments on: Why I’m not buying Biovest (BVTI) — yet

By: charles kaplan

charles kaplan — Wed, 17 Mar 2010 01:38:12 +0000

as a long time investor in biovest and a physician, i still strongly believe in the incredible benefit of the Biovaxid vaccine. they are presenting at a big conference on vaccines in april 2010. this will be the year.

By: Peet

Peet — Tue, 09 Mar 2010 21:15:16 +0000

Anyone have any idea why this stock is suddenly way up to $1.95+ (100% gain over the past week)? I see no news listed anywhere from this company or its parent Accentia. Are they presenting results somewhere soon, or a development in bankruptcy proceedings?

By: mike

mike — Tue, 09 Mar 2010 13:12:16 +0000

I bought 1500 shares of this stock 2 years ago at $.60 a share . Yesterday (March 8, 2010) it closed at $1.41 a share. I'll hold onto it.

By: Benjamin Grant

Benjamin Grant — Tue, 23 Feb 2010 20:06:43 +0000

Rumors are not good for BVTI stock owners.. looks like the author of this was correct indeed.

By: Homework and horses (ABPIQ, BVTI) | Microcap Speculator — microcapspeculator.net

Mon, 02 Nov 2009 13:05:14 +0000

[...] a lot of emails and comments on Biovest and Accentia. Some suggest that I need to do more homework on the bankruptcy proceedings for these two [...]

By: Moe

Moe — Sun, 07 Jun 2009 11:41:30 +0000

Do your homework and do some simple math, you are pickinig the wrong horse. BVTI is 75% owned by ABPIQ. ABPIQ has 51M shares, and BVTI has 97M shares. ABPIQ now at .40 and BVTI now at .61????

ABPIQ owes $32M in secured debt and 30M unsecured. BVTI owes 33.5M secured and 15M unsecured. Both are operating under chapter 11 with plans to emerge intact this fall, current with filings and listed. Partnerships in the works, sales through the Named Patient Program in EU = money to satisfy court with repayment schedule. Also a different drug Revimmune for MS in Partnership discussion and planned Phase 3 trial.

The very unusual upside here is because of the “Q.PK”. If it was not for this it would be trading more like DNDN and nowhere near where it is now. Once listed and Bio Analyst (just now watching and waiting) are able to report, we should be trading somewhere between $10-20 a share for ABPIQ. Both stocks will do well, but simple math will tell you ABPIQ is the horse you should be riding.

I predict that this will be your largest % mover over next 6 months. The “Q.PK” spefically is presenting a 4,000% move to $16.

Bottom line- don’t wait too long for better entry point looking at a few cents when it’s the dollars you should be looking at.

Your welcome

By: MS

MS — Sun, 07 Jun 2009 00:48:11 +0000

@steve: I understand a lot of people think the vaccine is going to be a huge hit. From my lay reading the data seemed positive, and my discussions with others more knowledgeable in these areas also suggested the vaccine has potential — which is why I am considering investing at a better entry point.

But I’m a trader and I consider timing to be just as important as stockpicking. Buying directly after major positive news hits is generally not a high percentage play. Are you suggesting that the data is so positive that the stock is unlikely to go down at all from here? Did you feel that way Monday? wrt future financings, do you believe there will be substantial dilution?

By: steve

steve — Sun, 07 Jun 2009 00:21:02 +0000

Sir/Madam – You have to be kidding me. Lets review the facts.Both Accentia and Biovest went into bankruptcy in Nov 2008. Both continue to trade.The majority holder (hopkins capital and CEO o’donnell) have provided DIP financing to continue operating. This vacine has a 10 yaer history and 95% of the people are still living vs 50% with current treatment. Disease free survival increased well over one year – name me another cancer vaccine that is even close to that.No toxicity, little side effects, increase in PCR negative vs standard of care. Come on do your home work.